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INTRODUCTION
The short-term outcomes of solid organ transplantation have 
markedly improved in the past few decades, largely due to im-
provements in immunosuppression and medical care. Cal-
cineurin inhibitor (CNI)-based “triple-drug” maintenance 
regimens are routinely employed in patients receiving lung trans-
plantation.1 The goal of immunosuppression in transplanta-
tion is long-term patient survival with healthy allografts, while 
minimizing complications that occur due to immunosuppres-
sive medications. However, lifelong medication increases the 
risk of renal dysfunction, severe infections, malignancies, and 
other critical comorbidities, thereby resulting in diminished 
quality of life and reduced rates of long-term survival.2
CNI nephrotoxicity is an important side effect of current im-
munosuppression strategies. Significant rates of postoperative 
renal dysfunction have been described in patients undergoing 
lung transplantation and those who had received CNI in the 
perioperative period.3 An option to prevent the occurrence of 
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postoperative renal function would be delaying CNI initiation 
after the early postoperative period, which is mainly charac-
terized by hemodynamic instability; the need for blood trans-
fusions inotropic agents, and vasopressors; and the occurrence 
of systemic inflammation, all of which contribute to fluctuating 
CNI pharmacokinetics and an increased risk of renal injury.4 
During this early postoperative phase, immunosuppression is 
due to the rapid depression of the adaptive immunity for the 
prevention of acute cellular rejection in all modalities. Basilix-
imab is a chimeric monoclonal antibody that selectively binds 
to the α–subunit (CD25) of interleukin-2 receptors on T-cells 
that are activated as a result of an immune response to the for-
eign antigens of newly transplanted organs.5 Furthermore, basil-
iximab has shown a favorable side effect profile after solid organ 
transplantation.5 Therefore, the early administration of basilix-
imab as an induction agent would allow a delayed CNI initia-
tion, minimizing its nephrotoxicity during the early perioper-
ative phase.
The goal of induction therapy is to prevent acute rejection 
without compromising the renal function during the early post-
operative period, particularly in recipients who are at a high-
risk for acute renal failure. To date, there is no consensus on the 
optimal agent for the induction regimen after lung transplanta-
tion. Our study aimed to determine the efficacy of basiliximab 
induction therapy followed by delayed CNI initiation in pre-
venting acute complications without compromising sufficient 
immunosuppression in the perioperative period for patients 




All adult recipients of lung transplantation between January 
2013 and December 2019 at the lung transplant center of Sev-
erance Hospital, Yonsei University College of Medicine were 
retrospectively reviewed. Initially, patients who underwent dou-
ble-lung transplantation without additional procedures, such 
as co-transplantation of other organs, or heart surgery were 
included. We also excluded patients supported by cardiopul-
monary bypass or central extracorporeal membrane oxygen-
ation (ECMO) during transplantation. This study was approved 
by the Institutional Review Board (IRB) of Severance Hospital 
of Yonsei University (IRB: 4-2020-0629). The IRB waived the 
requirement for obtaining informed consent from the patients.
Patients with at least one of the following risk factors were 
categorized as high-risk patients for postoperative renal dys-
function: 1) history of renal disease such as chronic renal fail-
ure, 2) poor baseline renal function [serum creatinine (sCr) 
>1.5 mg/dL or estimated glomerular filtration rate calculated 
with MDRD formula <60 mL/min], and 3) preoperative me-
chanical ventilation or ECMO care. Since August 2017, patients 
categorized as high-risk patients have routinely received a basi-
liximab induction regimen, while only a few selected patients 
had received such induction treatment before this date. There-
fore, we categorized the patients not only into the induction and 
non-induction groups, but also into the high-risk induction, 
high-risk non-induction, and low-risk groups for analysis. We 
also performed a subgroup analysis of the patients with preop-
erative ECMO support.
All patients followed our standard post-transplant protocol, 
including intensive unit care, administration of antibiotics, ex-
amination of blood parameters, evaluation of post-transplant 
status, and follow-up visits.
Immunosuppressant protocols
Our standard immunosuppressive regimen was based on a tri-
ple-drug combination of tacrolimus, mycophenolate mofetil 
(MMF), and corticosteroids. For the non-induction group, 1-mg 
tacrolimus was administered as a loading dose before surgery, 
and started after transplantation with target blood levels of 
10–15 mg/dL. All patients received 500-mg intravenous (IV) 
methylprednisolone before reperfusion, followed by IV admin-
istration of 0.5 mg/kg for 3 days. Then, we gradually tapered the 
dose to 0.25 mg/kg. One 2000-mg MMF dose was adminis-
tered preoperatively and maintained daily unless it resulted in 
leukopenia or liver dysfunction, in which case the dose was low-
ered or discontinued.
The basiliximab induction regimen consisted of IV adminis-
tration of a 20-mg dose at 2 hours before lung transplantation 
and a second 20-mg IV dose given on postoperative day (POD) 
4 without tacrolimus administration. Since basiliximab has a 
half-life of 7 days, our institutional policy was to resume tacroli-
mus on POD 7 at a dose of 1–2 mg, and gradually titrate it until 
the target serum levels were achieved.6
Perioperative infectious prophylaxis was based on broad-
spectrum antibiotics or adapted to pre-transplant resistance 
testing. All patients received a lifelong pneumocystic prophy-
laxis with trimethoprim-sulfamethoxazole. Cytomegalovirus 
prophylaxis with valganciclovir was maintained for at least 3 
months. IV or oral antifungal therapy was administered.
Assessment of postoperative outcomes
Postoperative acute kidney injury was defined as any of the 
following conditions: an elevation of sCr ≥0.3 mg/dL within 
48 hours or ≥1.5-fold elevation from the baseline value within 
7 days; a urine volume <0.5 mg/kg/hour for 6–12 hours; or the 
need for renal replacement due to metabolic acidosis and elec-
trolyte imbalance.7 Baseline sCr was measured immediately 
before transplantation. Postoperative sCr levels were measured 
immediately and 12 hours post-transplantation; on PODs 1, 2, 
3, and 7; and on the day of the patient’s first hospital discharge. 
We also collected the delta sCr (ΔsCr) values to assess renal 
function alterations, which were calculated as follows: post-
operative sCr level-baseline sCr. An increase in serum sCr in-
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dicated a worsening renal function.
Factors such as intraoperative hemodynamic instability, in-
traoperative transfusion, postoperative bleeding, and infections 
(microbes confirmed on culture and necessitating antibiotic 
treatment) that are potentially related to kidney injury were also 
collected.
Operative data, including ischemic and operative times, were 
collected. Postoperative outcomes, including ECMO weaning 
in the operating room, length of mechanical ventilation, pri-
mary graft dysfunction at 72 hours after surgery, respiratory and 
other complications, were recorded. Acute rejection was de-
fined according to the International Society of Heart and Lung 
Transplantation criteria.8
Statistics
Statistical analyses were performed using SPSS software ver-
sion 25 (IBM Corp., Armonk, NY, USA). Continuous variables 
are reported as the mean±standard deviation values for para-
metric values and the median [interquartile range] for non-
parametric values, and categorical variables are reported as 
frequencies (%). The Student’s t test and Mann-Whitney U test 
were used to compare continuous variables, whereas the chi-
squared or Fischer’s exact test was used to compare categori-
cal variables, when required. Differences in continuous vari-
ables among groups were examined using a one-way analysis 
of variance (ANOVA), followed by Bonferroni correction for 
multiple comparisons. Mixed ANOVA was used for comparing 
serial changes in sCr levels among groups, with induction treat-
ment as the in-between factor and time as the within factor 
(POD when the sCr levels were measured). Statistical signifi-
cance threshold was set at a p value of <0.05.
RESULTS
Demographic and clinical characteristics
Among 262 patients who underwent lung transplantation at 
the Department of Thoracic Surgery, Yonsei University College 
of Medicine from January 2013 to December 2019, 236 pa-
tients were included in the present study (Fig. 1).
Preoperative clinical features of patients are described in 
Table 1. Of the 236 patients, 17.4% (n=41) received a basilix-
imab induction regimen and 82.6% (n=195) received a routine 
triple-drug regimen without induction agents. The median 
follow-up duration was 685.0 (168.5;1368.5) days and 278.0 
(182.0;369.0) days for the non-induction and induction groups, 
respectively (p<0.001). The induction group was older than 
the non-induction group (mean age, 57.5±9.3 years vs. 52.7± 
12.5 years, p=0.006) and predominantly male (78.0% vs. 59.5%, 
p=0.040). In both groups, the most common pre-transplanta-
tion diagnosis was interstitial lung disease (78.0% and 72.8%). 
Preoperative comorbidities and kidney function of both groups 
were comparable. The induction group had a higher propor-
tion of patients who had been admitted before transplantation 
(95.1% vs. 47.7%, p<0.001) and had a longer hospitalization be-
fore transplantation [32.0 (23.0;72.0) days vs. 0.0 (0.0;20.0) days, 
p<0.001]. Besides, the induction group frequently received 
more care in the intensive care unit (ICU) (90.2% vs. 33.8%, 
p<0.001) and spent a significantly longer duration in the ICU 
[16.0 (11.0;28.0) days vs. 0.0 (0.0;8.0) days, p<0.001). Moreover, 
the induction group had a higher proportion of patients receiv-
ing pre-transplantation ECMO support (87.8% vs. 20.0%, p< 
0.001), and had longer durations of pre-transplantation ECMO 
support [12.0 (6.0;22.0) days vs. 0.0 (0.0;0.0) days, p<0.001).
Operative and postoperative outcomes
Table 2 shows the operative details and postoperative outcomes 
of all groups. There were no significant differences in the total 
operative time, intraoperative ECMO weaning rate, postoper-
ative ICU and hospital stay durations, and operative mortality 
between the induction and non-induction groups. Greater 
amounts of estimated blood loss and intraoperative transfu-
sion were observed in the induction group [2800.0 (2000.0; 
5000.0) vs. 2000.0 (1200.0;3450.0), p=0.003, and 2910.0 (2100.0; 
5350.0) vs. 2330.0 (1440.0;3600.0), p=0.010, respectively). The 
target tacrolimus level was reached earlier in the non-induction 
group [POD 4.0 (3.0;9.0) vs. 14.0 (10.0;17.0), p<0.001, respec-
tively], and the tacrolimus level was higher on the day the tar-
get level was achieved in the non-induction group [12.0 (10.8; 
13.9) vs. 10.8 (10.5;11.6), p<0.001, respectively]. Regarding 
postoperative complications, there were no statistically signif-
icant differences in the incidence of acute rejection or acute kid-
ney injury between the two groups. Culture-proven infection 
was less frequent in the induction than in the non-induction 
group (7.3% vs. 22.1%), although this difference was not statis-
tically significant.
The serial changes in sCr levels of both groups are present-
ed in Fig. 2A. Changes in sCr levels were comparable between 
the induction and non-induction groups (p=0.440).
Comparison of high-risk groups
We also divided the entire cohort into three groups according 
to a preoperative risk analysis for acute kidney injury. Of all 
262 cases of lung transplantation 
Severance Hospital, 
Yonsei University College of Medicine 
(2013. 01. 01–2019. 12. 31)
236 cases included
Excluded 26 cases
- Single lung transplantation (12 cases)
- Redo-transplantation (5 cases)
-  Combined procedures (7 cases) 
a. Multiorgan transplantation (4 cases) 
b. Cardiac surgery (3 cases)
- Intraoperative central ECMO (2 cases)
Fig. 1. Flow chart describing the selection of study participants.
167
Ha Eun Kim, et al.
https://doi.org/10.3349/ymj.2021.62.2.164
Table 1. Clinical and Demographic Characteristics of the Patients
Non-induction group (n=195) Induction group (n=41) p value
Male sex 116 (59.5) 32 (78.0) 0.040 
Age (yr)   52.7±12.5 57.5±9.3 0.006
BMI 20.8±3.7 22.7±4.8 0.017
Diagnosis 0.065
COPD and emphysema 6 (3.1) 4 (9.8)
Interstitial lung disease 142 (72.8) 32 (78.0)
Bronchiectasis 13 (6.7) 3 (7.3)
Others 34 (17.4) 2 (4.9)
Comorbidities
Diabetes mellitus 26 (13.3) 11 (26.8) 0.054
Hypertension 15 (7.7) 7 (17.1) 0.075
Chronic renal disease 19 (9.7) 4 (9.8) 1.000
Malignancies 29 (14.9) 1 (2.4) 0.056
Baseline creatinine levels (mg/dL)  0.65±0.22  0.53±0.20 0.003
Time on waiting list (days) 82.0 [24.0;171.0] 121.0 [29.0;244.0] 0.102
Pretransplantational admission 93 (47.7) 39 (95.1) <0.001
Pretransplantational admission duration (days) 0.0 [0.0;2.0] 32.0 [23.0;72.0] <0.001
Pretransplantational ICU care 66 (33.8) 37 (90.2) <0.001
Pretransplantational ICU care duration (days) 0.0 [0.0;8.0] 16 [11.0;28.0] <0.001
Pretransplantational ventilator care 60 (30.8) 37 (90.2) <0.001
Pretransplantational ventilator care duration (days) 0.0 [0.0;5.5] 14.0 [2.0;21.0] <0.001
Pretransplantational ECMO support 39 (20.0) 36 (87.8) <0.001
Pretransplantational ECMO support duration (days) 0.0 [0.0;0.0] 12.0 [6.0;22.0] <0.001
BMI, body mass index; COPD, chronic obstructive pulmonary disease; ECMO, extracorporeal membrane oxygenation; ICU, intensive care unit.
Data are presented as mean±standard deviation or n (%).
Table 2. Operative and Postoperative Outcomes
Non-induction group (n=195) Induction group (n=41) p value
Total operative time (hours) 5.0 [4.5;6.0] 6.0 [5.5;7.0] 0.001
Intraoperative ECMO weaning 114 (58.5) 25 (61.0) 0.902
Intraoperative transfusion amount (mL) 2330.0 [1440.0;3600.0] 2910.0 [2100.0;5350.0] 0.010
Estimated blood loss (mL) 2000.0 [1200.0;3450.0] 2800.0 [2000.0;5000.0] 0.003
Postoperative day when the target tacrolimus level was achieved (days) 4.0 [3.0;9.0] 14.0 [10.0;17.0] <0.001
Tacrolimus level on the day the target level was achieved (mg/dL) 12.0 [10.8;13.9] 10.8 [10.5;11.6] <0.001
Postoperative complications
Acute rejection 7 (3.6) 2 (4.9) 0.657
Postoperative bleeding requiring re-operation 27 (13.8) 8 (19.5) 0.493
Respiratory failure requiring tracheostomy 49 (25.1) 15 (36.6) 0.318
Bronchial dehiscence 16 (8.2) 1 (2.4) 0.334
Pulmonary artery stenosis 11 (5.6) 1 (2.4) 0.647
Acute kidney injury 62 (31.8) 9 (22.0) 0.288
Postoperative renal replacement therapy 40 (20.5) 7 (17.1) 0.775
Infection (culture proven) 43 (22.1) 3 (7.3) 0.051
Neurological complications 13 (6.7) 2 (4.9) 0.941
Gastrointestinal complications 43 (22.1) 4 (9.8) 0.115
Wound dehiscence 8 (4.1) 2 (4.9) 1.000
Postoperative ICU stay (first admission) (days) 8.0 [5.0;15.0] 7.0 [5.0;12.0] 0.489
Duration of postoperative hospital stay (days) 39.0 [25.0;76.5] 52.0 [30.0;96.0] 0.121
Duration of total hospital stay (days) 54.0 [32.0;98.5] 109.0 [61.0;160.0] 0.001
Surgery-related mortality (within 30 days) 10 (5.1) 1 (2.4) 0.738
ECMO, extracorporeal membrane oxygenation; ICU, intensive care unit.
Data are presented as n (%).
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patients included in the study, 55.9% (n=132) were categorized 
to the low-risk group, 17.4% (n=41) to the high-risk induction 
group undergoing a basiliximab induction regimen, and 26.7% 
(n=63) to the high-risk non-induction group undergoing a 
traditional triple-drug immunosuppression regimen. We per-
formed an analysis in the high-risk induction and high-risk 
non-induction groups, and presented the results in Table 3. 
The data from the low-risk group are shown as control values. 
The high-risk induction group had been listed for transplanta-
tion for a longer duration [121.0 (29.0;244.0) days vs. 26.0 (11.5; 
97.0) days, p=0.001] and was admitted for longer periods [32.0 
(23.0;72.0) days vs. 23.0 (13.0;37.0) days, p=0.003] before trans-
plantation compared to the high-risk non-induction group. 
The incidence and duration of pre-transplantation ECMO sup-
port were higher in the high-risk induction group [87.8% vs. 
61.9%, p=0.008; 12.0 (6.0;22.0) days vs. 6.0 (0.0;14.5) days, p= 
0.003], whereas the incidence of admitting ICU was higher in 
the high-risk non-induction group (93.7% vs. 90.2%, p=0.709). 
The amount of estimated blood loss was greater in the highrisk 
induction group [2800.0 (2000.0;5000.0) mL vs. 2100.0 (1400.0; 
3500.0) mL, p=0.066]. Regarding the postoperative complica-
tions, the incidence of acute rejection was not statistically signif-
icant between the two groups (4.9% vs. 7.9%, p=0.701). The high-
risk non-induction group showed a higher incidence of acute 
kidney injury (42.9% vs. 22.0%, p=0.048) and culture-proven in-
fection (30.2% vs. 7.3%, p=0.011). The incidence of neurologic 
and gastrointestinal complications was also higher in the high-
risk non-induction group (neurologic, 11.1% vs. 4.9%, p=0.477; 
gastrointestinal, 22.2% vs. 9.8%, p=0.169), although the differ-
ence was not statistically significant. Serial changes in sCr lev-
els in all groups are presented in Fig. 2B. At 2 days after surgery, 
ΔsCr in the high-risk induction and low-risk groups presented 
negative values, whereas that of the high-risk non-induction 
group was increased; however, the difference between groups 
was not statistically significant (p=0.723).
Comparison of induction and non-induction groups 
receiving preoperative ECMO support
Patients who received preoperative ECMO support were sep-
arately analyzed, and the results are shown in Table 4. Among 
the 75 patients who received preoperative ECMO support, 36 
(48%) received basiliximab induction treatment. Similar re-
sults were observed in the subgroup analysis. The incidence 
of acute rejection was not statistically different between the 
induction and non-induction groups (5.6% vs. 7.7%, p=1.000), 
but the non-induction group tended to have a higher incidence 
of acute kidney injury during the early postoperative phase 
(19.4% vs. 41.0%, p=0.076). Although not statistically different, 
the non-induction group also tended to have a higher inci-
dence of culture-proven infection and neurologic and gastro-
intestinal complications.
Changes in the average ΔsCr levels according to the pres-
ence or absence of an induction regimen are shown in Fig.  2C. 
Changes in the sCr levels were not significantly different be-
tween the induction and non-induction groups. Initially, the 
sCr levels of the induction group seemed to be elevated, but 
they stabilized over time.
DISCUSSION
The key findings of our study suggest that the basiliximab in-
duction regimen allows for a delayed initiation of tacrolimus, 
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Fig. 2. Changes in serum creatinine levels. (A) Comparison between the 
induction and non-induction groups, (B) comparison among groups 
categorized according to results of a risk analysis, and (C) comparison 
between the induction and non-induction groups receiving ECMO sup-
port. ECMO, extracorporeal membrane oxygenation. 
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Baseline creatinine levels (mg/dL) 0.53±0.20 0.58±0.26 0.293 0.67±0.19
Time on waiting list (days) 121.0 [29.0;244.0] 26.0 [11.5;97.0] 0.001 96.0 [46.0;189.5]
Pretransplantational admission 39 (95.1)   63 (100.0) 0.153 30 (22.7)
Pretransplantational admission duration (days) 32.0 [23.0;72.0] 23.0 [13.0;37.0] 0.003 0.0 [0.0;0.0]
Pretransplantational ICU care 37 (90.2) 59 (93.7) 0.709 7 (5.3)
Pretransplantational ICU care duration (days) 16.0 [11.0;28.0] 14.0 [8.0;21.0] 0.109 0.0 [0.0;0.0]
Pretransplantational ECMO support 36 (87.8) 39 (61.9) 0.008 0 (0.0)
Pretransplantational ECMO support duration (days) 12.0 [6.0;22.0] 6.0 [0.0;14.5] 0.003 0.0 [0.0;0.0]
Total operative time (hours) 6.0[5.5;7.0] 5.5 [5.0;6.0] 0.020 5.0 [4.25;6.0]
Intraoperative ECMO weaning 25 (61.0) 32 (50.8) 0.413 82 (62.1)
Intraoperative transfusion amount (mL) 2910.0 [2100.0;5350.0] 3100.0 [1935.0;4485.0] 0.808 2030.0 [1220.0;3255.0]
Estimated blood loss (mL) 2800.0 [2000.0;5000.0] 2100.0 [1400.0;3500.0] 0.066 1800.0 [1100.0;3350.0]
Postoperative day when the target tacrolimus level was achieved (days) 14.0 [10.0;17.0] 4.0 [3.0;9.0] 0.001 4.0 [3.0;9.0]
Tacrolimus level on the day the target level was achieved (mg/dL) 10.8 [10.5;11.6] 12.1 [10.8;13.8] 0.001 11.9 [10.8;14.0]
Postoperative complications
Acute rejection 2 (4.9) 5 (7.9) 0.701 2 (1.5)
AKI   9 (22.0) 27 (42.9) 0.048 35 (26.5)
Infection (culture proven) 3 (7.3) 19 (30.2) 0.011 24 (18.2)
Neurologic complications 2 (4.9)   7 (11.1) 0.477 6 (4.5)
Gastrointestinal complications 4 (9.8) 14 (22.2) 0.169 29 (22.0)
Duration of postoperative ICU stay (first admission; days) 7.0 [5.0;12.0] 10.0 [5.0;19.0] 0.197 7.0 [5.0;13.0]
Duration of postoperative hospital stay (days) 52.0 [30.0;96.0] 53.0 [33.5;91.5] 0.960 35.0 [25.0;60.5]
Duration of total hospital stay (days) 109.0 [61.0;160.0] 79.0 [55.0;121.0] 0.126 40.5 [27.0;78.0]
Surgery-related mortality (within 30 days) 1 (2.4) 6 (9.5) 0.240 4 (3.0)
AKI, acute kidney injury; ICU, intensive care unit; ECMO, extracorporeal membrane oxygenation.
Data are presented as n (%).
Table 4. Subgroup Analysis of Patients with Preoperative ECMO Support
Non-induction group (n=39) Induction group (n=36) p value
Baseline creatinine levels (mg/dL) 0.59±0.30 0.52±0.18 0.003
Time on waiting list (days) 26.0 [11.0;89.0] 105.0 [28.5;237.5] 0.003
Pretransplantational admission duration (days) 30.0 [16.5;39.5] 32.0 [23.0;71.5] 0.064
Pretransplantational ICU care duration (days) 16.0 [9.5;21.0] 16.5 [11.5;27.0] 0.316
Pretransplantational ECMO support duration (days) 2.0 [9.0;18.5] 13.0 [9.5;22.5] 0.286
Total operative time (hours) 5.5 [5.0;6.8] 6.0 [5.5;7.0] 0.254
Intraoperative ECMO weaning 16 (41.0) 21 (58.3) 0.205
Intraoperative transfusion amount (mL) 3400.0 [1875.0;4770.0] 2880.0 [2072.5;5775.0] 0.958
Estimated blood loss (mL) 2400.0 [1825.0;3900.0] 2700.0 [1900.0;5050.0] 0.311
Postoperative day when the target tacrolimus level was achieved (days) 5.0 [3.0;10.0] 14.0 [10.0;17.0] <0.001
Tacrolimus level on the day the target level was achieved (mg/dL) 11.5 [10.8;13.6] 10.8 [10.2;11.8] 0.024
Postoperative complications
Acute rejection 3 (7.7) 2 (5.6) 1.000
AKI 16 (41.0)   7 (19.4) 0.076
Infection (culture proven) 11 (28.2) 3 (8.3) 0.056
Neurologic complications 3 (7.7) 2 (5.6) 1.000
Gastrointestinal complications   9 (23.1)   4 (11.1) 0.288
Duration of postoperative ICU stay (first admission) (days) 12.0 [6.0;20.5] 6.5 [5.0;12.0] 0.031
Duration of postoperative hospital stay (days) 44.0 [31.5;83.5] 51.5 [30.0;93.5] 0.687
Duration of total hospital stay (days) 79.0 [57.0;118.5] 107.5 [61.0;156.5] 0.215
Surgery-related mortality (within 30 days)   4 (10.3) 1 (2.8) 0.360
AKI, acute kidney injury; ECMO, extracorporeal membrane oxygenation; ICU, intensive care unit.
Data are presented as n (%).
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tients who are at an increased risk of postoperative renal im-
pairment. In addition, there was no evidence of increased acute 
rejection with this regimen. This favorable early experience 
could be applied as a routine protocol for lung transplant re-
cipients at risk for postoperative renal dysfunction.
The rationale for immunosuppression induction with de-
layed of CNI agent initiation in lung transplantation is based on 
the outcomes of previous studies on other solid organ trans-
plantations.5,9,10 However, researchers have not yet reached a 
consensus regarding the application of immunosuppression 
induction for lung transplantation patients. Few studies have 
investigated this issue; however, these studies had small sam-
ple sizes and were retrospective in nature. Several reports have 
demonstrated the efficacy of induction agents, such as basil-
iximab, with relatively low cumulative burdens in comparison 
to conventional maintenance, which is the reason why basili-
simab induction is still not a routine regimen for lung trans-
plantation.1,11 To the best of our knowledge, no study has been 
conducted to date regarding immunosuppression induction 
with delayed CNI initiation in the prevention of acute kidney 
injury during the perioperative phase of lung transplantation.
Tacrolimus is the first-line CNI, and it is typically initiated 
on the first POD and maintained throughout the lifetime of 
the patient. A second CNI became available for use in 1997.2 
While acute and chronic rejection may be improved with tacro-
limus, adverse effects, such as nephrotoxicity, affect surviv-
al.12,13 Tacrolimus leads to renal impairment as it causes vaso-
constriction of the afferent and efferent glomerular arterioles, 
and evidence has demonstrated that elevated whole-blood ta-
crolimus peak concentrations are associated with acute kidney 
injury during the early postoperative period.3,13 In this regard, 
discrepancies exist regarding the initiation of tacrolimus when 
there is evidence of postoperative renal complications.14 As the 
acuity and severity of end-stage respiratory failure are wors-
ened in patients on waiting lists, more patients are likely to pos-
sess the risk factors for compromised renal function. Therefore, 
in these patients, early postoperative management of lung 
transplantation becomes more delicate. The basiliximab induc-
tion strategy described here could provide an alternative im-
munosuppression regimen to avoid acute renal impairment 
observed with a CNI regimen in patients at increased risk of 
renal failure. 
This study has some limitations. It is a retrospective analysis 
using single-center data, and the study cohort is relatively small. 
We resumed tacrolimus on POD 7 in the induction group 
since the half-life of basiliximab is 7 days, and in references to 
other solid organ transplantations; however, there are no exact 
criteria for when to resume tacrolimus administration in lung 
transplant patients with basiliximab induction.12,15,16 A pro-
spective, randomized study is needed to provide deeper in-
sights into the role and standard of basiliximab induction treat-
ment. Furthermore, the effect of the era in which treatment was 
provided cannot be excluded, since basiliximab induction 
was introduced recently. It is possible that the results might 
partially reflect the recent improvements in surgical strategies 
and postoperative care. Another limitation of this study is that 
perioperative renal injury was assessed by changes in sCr lev-
els and reductions in urine output, rather than by Cr clearance, 
proteinuria, or histopathologic confirmation from renal biop-
sies. This could have resulted in missed tubulointerstitial inju-
ry, and may have affected the evaluation of renal injury. 
In conclusion, basiliximab induction with delayed tacroli-
mus initiation in patients who are at risk for renal impairment 
may reduce the incidence of acute renal failure during the ear-
ly postoperative period, without increasing the risk of acute re-
jection. Further studies using prospective, randomized clini-
cal trials and long-term follow-up data are warranted.
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